 |
|
Tests for Carcinoembryonic AntigenRole in Diagnosis and Management of Cancer
Phil Gold, MD, PhD, FRCP(C);
Samuel O. Freedman, MD, FRCP(C)
JAMA. 1975;234(2):190-192.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
THE CARCINOEMBRYONIC antigen (CEA) of the human digestive system was first described in 1965 after a series of experiments involving the immunization of heterologous animals with human-colon cancer-tissue extracts and the preparation of antitumor antisera under well-defined conditions. The CEA has been purified, identified as a fairly large glycoprotein, and partly characterized with regard to its protein and carbohydrate constituents. Several review articles1-4 detail these developments. At least a portion of the CEA of colon cancer cells has been localized, by immunoelectron microscopy, to the cellular glycocalyx.1 From this position, where it may represent a structural constituent of the glycocalyx or material in transit from the cytoplasm across the cell membrane, the CEA is apparently quite easily released into the surrounding body fluids.
Radioimmunoassay Techniques
Since 1969, a number of sensitive and reproducible radioimmunoassays for CEA have been developed that are capable of detecting nanogram quantities of this
. . . [Full Text PDF of this Article]
Author Affiliations
From the Division of Clinical Immunology and Allergy, Montreal General Hospital, and the McGill University Medical Clinic, Montreal General Hospital Research Institute, Montreal. Dr Gold is an Associate of the Medical Research Council of Canada, Ottawa.
Footnotes
Reprint requests to Division of Clinical Immunology and Allergy, Montreal General Hospital, 1650 Cedar Ave, Montreal, Quebec, H3G 1A4 (Dr Gold).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
